Bank of Hawaii Sells 28,766 Shares of AMBEV S A/S (NYSE:ABEV)

Share on StockTwits

Bank of Hawaii reduced its position in shares of AMBEV S A/S (NYSE:ABEV) by 38.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,135 shares of the company’s stock after selling 28,766 shares during the quarter. Bank of Hawaii’s holdings in AMBEV S A/S were worth $213,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC bought a new position in shares of AMBEV S A/S in the second quarter valued at about $28,000. FTB Advisors Inc. raised its position in shares of AMBEV S A/S by 345.2% in the second quarter. FTB Advisors Inc. now owns 8,170 shares of the company’s stock valued at $37,000 after purchasing an additional 6,335 shares during the period. Signaturefd LLC raised its position in shares of AMBEV S A/S by 75.5% in the second quarter. Signaturefd LLC now owns 9,288 shares of the company’s stock valued at $43,000 after purchasing an additional 3,996 shares during the period. Pacer Advisors Inc. bought a new position in shares of AMBEV S A/S in the second quarter valued at about $48,000. Finally, Cambridge Investment Research Advisors Inc. bought a new position in shares of AMBEV S A/S in the second quarter valued at about $49,000. 7.66% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have issued reports on ABEV shares. UBS Group reiterated a “sell” rating and set a $3.90 price objective (down from $4.30) on shares of AMBEV S A/S in a research note on Friday, November 15th. Zacks Investment Research upgraded shares of AMBEV S A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 13th. ValuEngine downgraded shares of AMBEV S A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Itau BBA Securities downgraded shares of AMBEV S A/S from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 8th. Finally, Barclays downgraded shares of AMBEV S A/S from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, August 27th. One analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. AMBEV S A/S currently has a consensus rating of “Hold” and an average target price of $4.97.

ABEV stock opened at $4.21 on Monday. The stock has a market capitalization of $66.21 billion, a P/E ratio of 22.16, a price-to-earnings-growth ratio of 3.98 and a beta of 0.69. The company has a current ratio of 1.33, a quick ratio of 1.05 and a debt-to-equity ratio of 0.07. AMBEV S A/S has a 12 month low of $3.77 and a 12 month high of $5.45. The firm has a 50-day moving average price of $4.35 and a 200-day moving average price of $4.59.

AMBEV S A/S Company Profile

Ambev SA, through its subsidiaries, produces, distributes, and sells beer, draft beer, carbonated soft drinks (CSD), other non-alcoholic beverages, malt, and food products in the Americas. It operates through three segments: Latin America North, Latin America South, and Canada. The company offers beer primarily under the Skol, Brahma, Antarctica, Brahva, Brahva Gold, Extra, Budweiser, Bud Light, Stella Artois, Corona, Modelo Especial, Beck, Leffe, Hoegaarden, Presidente, Brahma Light, President Light, Bohemia, The One, Quilmes Clásica, Paceña, Taquiña, Huari, Becker, Báltica, Ouro Fino, Pilsen, Patricia, Labatt Blue, Alexander Keith's, Kokanee, Banks, and Deputy brands.

Featured Article: Asset Allocation

Want to see what other hedge funds are holding ABEV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMBEV S A/S (NYSE:ABEV).

Institutional Ownership by Quarter for AMBEV S A/S (NYSE:ABEV)

Receive News & Ratings for AMBEV S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMBEV S A/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.